Magnetic control of gene delivery in vivo
This disclosure describes a composition and method of magnetic nanoparticles (MNP) that are bound to a baculovirus (BV). The MNP-BV can be systemically administered to a patient, and a strong magnetic field applied to the target tissue, thus allowing uptake and expression only in the target tissue. Off-target effects are not seen because the MNP-BC is inactivated by the complement system outside of the magnetic field.
1. A method of targeted in vivo gene editing, said method comprising:
a) packaging an expression vector encoding a CAS9 or dCAS9 protein, single or multiple guide RNAs and an optional donor template into a baculovirus vector (BV), wherein said guide RNA and said optional donor template have homology to one or more gene(s) that is to be edited;
b) attaching a plurality of magnetic nanoparticles (MNP) of <200 nm average size to said BV to make MNP-BV, wherein said MNP:BV ratio is at least 500:1;
c) introducing said MNP-BV to a patient comprising said gene(s) to be edited, wherein the MNP-BV contacts the patient's blood;
d) applying a magnetic field to a targeted tissue within 30 minutes of said introducing step c, without applying said magnetic field to non-targeted tissue, so that the MNP-BV are only taken up and expressed in cells in said targeted tissue and MNP-BV is inactivated by a complement system outside of the magnetic field; and
e) thereby editing said gene(s) only in said targeted tissue in said patient.
2. The method of claim 1 , wherein said magnetic field is at least 0.1 Tesla.
3. The method of claim 1 , wherein said gradient of the magnetic field is at least 0.1 Tesla/m.
4. The method of claim 1 , wherein said magnetic field is applied within 10 minutes of said introducing step c.
5. The method of claim 4 , wherein said magnetic field is applied for at least 30 minutes.
6. The method of claim 1 , wherein said magnetic field is applied for at least 60 minutes.
7. The method of claim 1 , wherein said MNP:BV ratio is at least 10 4 :1.
8. The method of claim 2 , wherein said MNP:BV ratio is at least 10 4 :1.
9. The method of claim 1 , wherein said guide RNA is a synthetic guide RNA comprising a gRNA and a trRNA.
10. A method of targeted in vivo gene editing, said method comprising:
a) packaging an expression vector encoding a CRISPR nuclease, single or multiple guide RNAs and an optional donor template into a baculovirus vector (BV), wherein said guide RNA and said donor template have homology to one or more gene(s) that is to be edited in a targeted tissue;
b) attaching a plurality of magnetic nanoparticles (MNP) to said BV to make MNP-BV, wherein a ratio of MNP to BV is at least 500:1 and the MNPs have an average size smaller than 200 nm;
c) systemically introducing said MNP-BV to a patient having said gene to be edited;
d) applying a magnetic field of at least 0.1 Tesla and 0.1 Tesla/m to said targeted tissue within 10 minutes of said introducing step c, without applying said magnetic field to non-targeted tissue, so that the MNP-BV are only taken up and transiently expressed in cells in said targeted tissue and MNP-BV is inactivated by a complement system in said patient outside of the magnetic field; and
e) thereby editing said gene only in said targeted tissue in said patient.
11. The method of claim 10 , wherein said MNP are made with iron oxide nanoparticles.
12. The method of claim 10 , wherein said MNP are made with iron(III) oxide nanoparticles and said nanoparticles are coated with one or more biocompatible polymers.
13. The method of claim 10 , wherein said MNP are made with magnetite crystals of 10-50 nm and said crystals inside a biocompatible phospholipid micelle.
14. The method of claim 12 , wherein said nanoparticles are conjugated with ligands that bind to the BV surface.
15. The method of claim 10 , wherein said MNP:BV ratio is at least 10 4 :1.